The company has advanced its next‑generation tamper‑evident syringe closure from design finalization to industrialization ahead of a planned 2027 launch to strengthen its position in prefilled drug‑delivery solutions.

A new RSV A-strain challenge agent has been introduced by SGS to enhance CHIM studies and accelerate vaccine development. The breakthrough aims to generate more accurate, data-driven insights into RSV infection and immune response.

The companies will leverage GSK’s scientific expertise with LTZ’s immune engager platform to develop new first-in-class MCE therapies for the treatment of hematologic cancers and solid tumors.

Regeneron’s investigational gene therapy, DB-OTO, has been found to provide meaningful improvements in hearing for nearly all of the participants in the CHORD clinical trial.

Led by researchers at the University of Liverpool, a team of international scientists have discovered a new, potent class of antibiotics that will help in the fight against antimicrobial resistance.

At the 15th Drug Delivery & Formulation Summit in Boston, Nanoform unveiled proof‑of‑concept data demonstrating new approaches to biologic drug delivery.

In a financial report webcast, the Norwegian biotech presented breakthrough circVec-AAV data showing up to 40x higher protein expression than traditional mRNA-AAVs.

The grant money will be used by the biotechs to develop innovative targeted lipid nanoparticles that contain novel immune-silent DNA constructs for in vivo CAR T therapy.

The company’s research in a well-established rodent model has shown that EB-003 has potential as an effective treatment for post-traumatic stress disorder, representing an opportunity in an underserved market.

Business Finland is providing Nanoform with a EUR 5 million R&D loan to be used to accelerate the clinical development of the nanoformulated version of apalutamide through to the pivotal bioequivalence study.

The latest studies on the mechanism of action for LIB-01 have demonstrated that the drug targets the underlying nerves and vascular structures that are involved in penile erections.

Circio presented the enhanced in vivo data for its circVec platform in viral and non-viral vectors at ASGCT 2025.

The Michael J. Fox Foundation for Parkinson’s Research and the Luxembourg National Research Fund have provided funding for two separate projects assessing Accure Therapeutics’ ACT-02 for the treatment of Parkinson’s disease.

Through analysis of historical vaccination program data, researchers have demonstrated a persistent link between the live-attenuated zoster vaccination and a lower incidence of dementia.

BioDuro, the global contract research, development and manufacturing (CRDMO) company, has opened a new state-of-the-art laboratory in Shanghai, China for the synthesis of high-potency APIs for the pharmaceutical industry.

Novartis' Fabhalta® (iptacopan), an oral drug targeting the alternative complement pathway, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for treating a rare kidney disease in adults, C3 glomerulopathy (C3G).

French biotech, SeaBeLife's, has announced promising preclinical trial results for its drug candidate, SBL03, an ophthalmic gel aimed at treating geographic atrophy (GA), a severe form of age-related macular degeneration (dry AMD). The gel - a dual inhibitor of regulated necrotic cell death - demonstrated significant protection of retinal structure and function after repeated topical applications.

Pharmaceutical packaging company, SCHOTT Pharma, has introduced its SCHOTT TOPPAC® infuse polymer syringe system; a new cap design for prefillable polymer syringes featuring tamper evidence at the individual syringe level.

Medical device company, Terumo, has announced the launch of its injection filter needle, marking the first step in its INFINO™ Development Program. The innovative needle design enhances safety and efficacy in hypodermic and intravitreal injections by incorporating a built-in filter to prevent the injection of particulates.

An AI proof-of-concept study from Dandelion Health has identified an additional 44 million lower-risk cardiovascular patients who could benefit from a GLP-1 treatment. Using inclusion criteria similar to the Novo Nordisk-sponsored trial that helped convince the FDA that Wegovy had heart benefits, Dandelion examined whether GLP-1 use might reduce the risk of major adverse cardiac events such as heart attack or stroke in overweight and obese patients in lower-risk patients that didn’t have severe pre-existing cardiovascular disease.